1 completed, 1 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Atlas Molecular Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP ATL-001 (Ciclopirox oral solution) - Congenital Erythropoietic Porphyria (CEP) | Phase 1 / Phase 2 | Recruiting | Atlas Molecular Pharma | 6 | 2026-01-29 | 2026-03-24 |
| Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers Ciclopirox Olamine Oral, Placebo - Adverse Effect of Drugs and Medicaments in Therapeutic Use | Phase 1 | Completed | Atlas Molecular Pharma | 42 | 2023-03-31 | 2024-07-24 |
Ciclopirox (2)
United States (2)